Last reviewed · How we verify
Experimental drug
Experimental drug is a Small molecule drug developed by IlDong Pharmaceutical Co Ltd. It is currently in Phase 3 development. Also known as: Tilelizumab combined with chemotherapy, CAP, sintilimab ,bevacizumab and TP chemotherapy.
Experimental drug works by targeting a specific molecular pathway to produce a therapeutic effect.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Experimental drug |
|---|---|
| Also known as | Tilelizumab combined with chemotherapy, CAP, sintilimab ,bevacizumab and TP chemotherapy |
| Sponsor | IlDong Pharmaceutical Co Ltd |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of action is not well understood, but it is believed to involve the modulation of a key cellular process.
Approved indications
Common side effects
Key clinical trials
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia (PHASE2)
- A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (PHASE1)
- Study of TGM-312-SC01 in Healthy Participants and Adults With MASH (PHASE1, PHASE2)
- Clinical Evaluation of an Experimental Remineralization Product (NA)
- MK-7075 (Miransertib) in Proteus Syndrome (PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Experimental drug CI brief — competitive landscape report
- Experimental drug updates RSS · CI watch RSS
- IlDong Pharmaceutical Co Ltd portfolio CI
Frequently asked questions about Experimental drug
What is Experimental drug?
How does Experimental drug work?
Who makes Experimental drug?
Is Experimental drug also known as anything else?
What development phase is Experimental drug in?
Related
- Manufacturer: IlDong Pharmaceutical Co Ltd — full pipeline
- Also known as: Tilelizumab combined with chemotherapy, CAP, sintilimab ,bevacizumab and TP chemotherapy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing